PCPing Chen

Ping Chen

*This is an algorithmically generated author record based on publicly available information.

Ping Chen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Wenguang Jia

    Affiliations The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi Province, China, NHC Key Laboratory of Thalassemia Medicine, Nanning, Guangxi Province, China, Key Laboratory of Thalassemia Medicine, Chinese Academy of Medical Sciences, Nanning, Guangxi Province, China, Guangxi Key Laboratory of Thalassemia Research, Nanning, Guangxi Province, China

    4 shared publications
  • Hengying Zhu

    NHC Key Lab Thalassemia Med, Nanning 530021, Guangxi, Peoples R China

    3 shared publications
  • Guifang Huang

    Baise Maternal & Child Hlth Hosp, Dept Eugen Genet, Baise 533000, Guangxi, Peoples R China

    1 shared publication
  • Hongyu Wei

    Guangxi Med Univ, Pharmaceut Coll, Dept Organ Chem & Med Chem, Nanning 530021, Guangxi Zhuang, Peoples R China

    1 shared publication
  • Houfeng Huang

    Baise Maternal & Child Hlth Hosp, Dept Ultrasound Imaging, Baise 533000, Guangxi, Peoples R China

    1 shared publication
  • Huifeng Han

    Berry Genom Co Ltd, Dept Bioinformat, Beijing 102206, Peoples R China

    1 shared publication

Latest Publications

  • Open Access

    A novel homozygous intronic variant affecting splicing in the RYR1 gene contributes to fetal hydrops

    by Wei Hou, Guifang Huang, Hongyu Wei, Wenwei Li, Houfeng Huang, Yuling Qiu, Hengying Zhu, Huifeng Han, Ping Chen, Xue Zhang


  • Open Access

    Integration of targeted sequencing and pseudo-tetraploid genotyping into clinically assisted decision support for β-thalassemia invasive prenatal diagnosis

    by Wenguang Jia, Jiying Shi, Hengying Zhu, Xiaojing Wu, Yayun Ling, Ping Chen

    Background: The high prevalence of β-thalassemia indicates the severe medical burden in Guangxi province in China. Millions of thousands of prenatal women with healthy or thalassemia-carrying fetuses received an unnecessary prenatal diagnosis. We designed a prospective single-center proof-of-concept study to evaluate the utility of a noninvasive prenatal screening method in the stratification of beta-thalassemia patients before invasive procedures. Methods: Next-generation and optimized pseudo-tetraploid genotyping-based methods were utilized in preceding invasive diagnosis stratification to predict the mater-fetus genotype combinations in cell-free DNA, which is from maternal peripheral blood. Populational linkage disequilibrium information with additional neighboring loci to infer the possible fetal genotype. The concordance of the pseudo-tetraploid genotyping with the gold standard invasive molecular diagnosis was used to evaluate the effectiveness of this method. Results: 127 β-thalassemia carrier parents were consecutively recruited. The total genotype concordance rate is 95.71%. The Kappa value was 0.8248 for genotype combinations and 0.9118 for individual alleles. Conclusion: This study offers a new approach to picking out the health or carrier fetus before invasive procedures. It provides valuable novel insight into patient stratification management on β-thalassemia prenatal diagnosis.


  • Construction and Analysis of a Long Non-Coding RNA (lncRNA)-Associated ceRNA Network in β-Thalassemia and Hereditary Persistence of Fetal Hemoglobin

    by Wenguang Jia, Siyuan Jia, Ping Chen, Yunyan He

    BACKGROUND:Higher fetal hemoglobin (HbF) levels can ameliorate the clinical severity of ß-thalassemia. The use of integrative strategies to combine results from gene microarray expression profiling, experimental evidence, and bioinformatics helps re...


  • A Novel Mutation at HBB: c.91delA (Codon 30, –A) Causing β-Thalassemia in a Chinese Family

    by Wenguang Jia, Weidong Wang, Hengying Zhu, Ping Chen

    β-Thalassemia is a genetic disease characterized by the defective synthesis of the hemoglobin tetramer β-globin chains. So far, a number of mutations have been identified and associated with this genetic disease. A high incidence of thalassemia has been found in Guangxi (China). Herein, we report a case of a patient with slightly increased HbA2 levels (4.6%). Based on the clinical data and laboratory findings, the patient was diagnosed with β-thalassemia. Routine genetic screening tests were negative. Sequencing revealed an A deletion at codon 30 (HBB: c.91delA) and the genotype of this patient was βCD30M/β. This mutation changes the splice receptor site of intron 1 from AG to GG, which likely abolishes splicing at the normal 5′ splicing site and may cause β0-thalassemia. Based on hematological and clinical evaluations, this novel mutation was regarded as a β0-thalassemia allele. A homozygosity or compound heterozygosity of this mutation and other β0-thalassemia alleles can lead to severe thalassemia disease.


  • Open Access

    Raman characterizations of red blood cells with β-thalassemia using laser tweezers Raman spectroscopy

    by Wenguang Jia, Ping Chen, Wenqiang Chen, Yongqing Li

    This study aimed to study the differences in Raman spectra of red blood cells (RBCs) among patients with β-thalassemia and controls using laser tweezers Raman spectroscopy (LTRS) system. A total of 33 patients with β-thalassemia major, 49 with β-thalassemia minor, and 65 controls were studied. Raman spectra of RBCs for each sample were recorded. Principal component analysis (PCA), one-way analysis of variance (ANOVA), and independent-sample t test were performed. The intensities of Raman spectra of β-thalassemia (major and minor) RBCs were lower than those of controls, especially at bands 1546, 1603, and 1619 cm–1. The intensity ratio of band 1546 cm–1 to band 1448 cm–1 demonstrated that there was a significant difference between the spectra of β-thalassemia major (mostly below 2.15) and those of controls. The spectra of controls could be well distinguished from those of β-thalassemia major using PCA. After normalization, the spectra of two different genotypes with β0/β0 mutations mainly overlapped, while those with β+/β+ mutations had lower intensity at bands 1546, 1603, and 1619 cm–1. The present study provided Raman characteristics of RBCs in patients with β-thalassemia major and supported the use of LTRS as a method for screening β-thalassemia major. The recognition rate for β-thalassemia minor needs to be further improved.